Diverse insulin pump algorithms demand personalised approaches in diabetes care

As automated insulin delivery systems become widespread, clinicians must navigate a growing variety of algorithms and features to tailor treatment for individual patients, highlighting the importance of understanding device distinctions and patient preferences.

Automated insulin delivery systems are now common enough that the differences between their algorithms matter in day-to-day diabetes care, Erin Henry told attendees at the Association of Diabetes Care & Education Specialists annual meeting, according to Healio. Henry, a nurse practitioner at North Atlanta Endocrinology and Diabetes in Georgia, said clinicians can no longer assume pump software works the same way across brands, because the rise of newer systems has brought a wider range of designs and settings. Reviews in the medical literature have also tracked that shift, noting that automated insulin delivery has evolved from a niche technology into a broad category with multiple control approaches.

That variation starts with the way a pump decides basal insulin. Some systems use a total daily dose approach, in which the device sets the basal rate automatically and the user cannot directly alter it. Others use adaptive basal models, where changes to programmed basal settings can still influence outcomes because the algorithm adjusts around them. Henry said understanding that distinction is essential when clinicians are trying to solve problems such as dawn phenomenon, because a change that helps on one pump may do nothing on another. Earlier reviews in Diabetes Spectrum and other medical journals have similarly described the field as a mix of control strategies, including proportional-integral-derivative systems, model predictive control and other hybrid approaches.

Henry said there is no single best algorithm for everyone. Instead, the right system depends on how much interaction a person wants, whether they prefer tubing or a tubeless device, and which continuous glucose monitor they are willing to use. She also stressed that clinicians should know the extra features built into each platform, such as exercise modes, temporary basal settings, extended boluses and pre-meal presets, because those tools can be as important as the algorithm itself in real-world care. A recent comparison of U.S. systems from Taking Control Of Your Diabetes highlighted the differences among products such as Tandem Control-IQ+, Medtronic MiniMed 780G, Insulet Omnipod 5, Beta Bionics iLet and Sequel twiist.

Her advice also differed by diabetes type. For people with type 2 diabetes, Henry said she looks more often at pumps with larger reservoirs, since insulin needs are generally higher. For people with type 1 diabetes, she tends to make smaller dose changes and places greater emphasis on site failure education, because insulin interruption can lead to diabetic ketoacidosis more quickly. A consensus report on automated insulin delivery in clinical practice has likewise underscored the need for patient education and close monitoring, especially when insulin reserve is limited. Henry added that clinicians should be especially cautious when patients start a GLP-1 drug, because appetite often falls while insulin requirements can drop sharply.

For follow-up, Henry said stable patients can usually be reviewed at routine three-month visits, while those with poor control may need checks every four to six weeks. Pregnant patients need much closer oversight. When reviewing downloads, she said the most useful questions are how much time the pump spends in automation, how often the patient boluses, whether boluses are entered manually or through the calculator, and how basal and bolus insulin compare over time. Henry said a week of daily reports, alongside the ambulatory glucose profile summary, often gives the clearest picture of what is going wrong and what needs to change.